These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 1108645)

  • 21. [Prospective study of favorable factors in follow-up of drug addicted patients--apropos of 257 patients of the Cassini Center in Paris].
    Goeb JL; Coste J; Bigot T; Ferrand I
    Encephale; 2000; 26(6):11-20. PubMed ID: 11217533
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-outcome of anxiety treatment intervention in primary care in Hungary.
    Zámbori J; Szádóczky E; Rózsa S; Füredi J
    J Ment Health Policy Econ; 2002 Sep; 5(3):115-20. PubMed ID: 12728198
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Treatment adherence in schizophrenia. A comparison between patient's, relative's and psychiatrist's opinions].
    Giner J; Cañas F; Olivares JM; Rodriguez A; Burón JA; Rodríguez-Morales A; Roca M
    Actas Esp Psiquiatr; 2006; 34(6):386-92. PubMed ID: 17117335
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Using King's Goal Attainment Theory to facilitate drug compliance in a psychiatric patient].
    Cheng MY
    Hu Li Za Zhi; 2006 Jun; 53(3):90-7. PubMed ID: 16767629
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Attitudes toward medication in inpatients with schizophrenia: a cluster analytic approach.
    Santone G; Rucci P; Muratori ML; Monaci A; Ciarafoni C; Borsetti G
    Psychiatry Res; 2008 Apr; 158(3):324-34. PubMed ID: 18262656
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Substance abuse and the management of medication nonadherence in schizophrenia.
    Wilk J; Marcus SC; West J; Countis L; Hall R; Regier DA; Olfson M
    J Nerv Ment Dis; 2006 Jun; 194(6):454-7. PubMed ID: 16772865
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Psychosocial and socio-demographic correlates of medication compliance among people with schizophrenia.
    Tsang HW; Fung KM; Corrigan PW
    J Behav Ther Exp Psychiatry; 2009 Mar; 40(1):3-14. PubMed ID: 18417098
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The natural course of schizophrenia and effective maintenance drug treatment.
    Davis JM; Andriukaitis S
    J Clin Psychopharmacol; 1986 Feb; 6(1 Suppl):2S-10S. PubMed ID: 2870087
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Medication-related attitudes of chronic schizophrenic patients. A follow-up study after psycho-educational intervention].
    Hornung WP; Schonauer K; Feldmann R; Mönking HS
    Psychiatr Prax; 1998 Jan; 25(1):25-8. PubMed ID: 9530765
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Compliance in the treatment of schizophrenia -- results of an expert survey in Saxony and Saxony-Anhalt].
    Giessler A; Born A; Helm H; Puschner B; Becker T
    Psychiatr Prax; 2005 Oct; 32(7):349-57. PubMed ID: 16220419
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].
    Bralet MC; Navarre M; Eskenazi AM; Lucas-Ross M; Falissard B
    Encephale; 2008 Dec; 34(6):557-62. PubMed ID: 19081451
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Treatment adherence as a social ability: a case of patients with schizophrenia].
    Baudrant-Boga M; Holtzmann J; Allenet B; Debeauchamp I; Giraud-Baro E
    J Pharm Belg; 2009 Sep; (3):91-8. PubMed ID: 19873850
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables.
    Naber D
    Int Clin Psychopharmacol; 1995 Sep; 10 Suppl 3():133-8. PubMed ID: 8866775
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The risks and benefits of clozapine versus chlorpromazine.
    Claghorn J; Honigfeld G; Abuzzahab FS; Wang R; Steinbook R; Tuason V; Klerman G
    J Clin Psychopharmacol; 1987 Dec; 7(6):377-84. PubMed ID: 3323261
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drugs and the quality of life: the patient's point of view.
    Diamond R
    J Clin Psychiatry; 1985 May; 46(5 Pt 2):29-35. PubMed ID: 2859278
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The P 300 potential in schizophrenia].
    Laurent A; Garcia-Larrea L; Dalery J; Terra JL; D'Amato T; Marie-Cardine M; Mauguière F
    Encephale; 1993; 19(3):221-7. PubMed ID: 8275907
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Subjective response to antipsychotic drugs: failure to replicate predictions of outcome.
    Ayers T; Liberman RP; Wallace CJ
    J Clin Psychopharmacol; 1984 Apr; 4(2):89-93. PubMed ID: 6707245
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sociotherapy and the prevention of relapse among schizophrenic patients: an artifact of drug?
    Hogarty GE; Ulrich R; Goldberg S; Schooler N
    Proc Annu Meet Am Psychopathol Assoc; 1976; (64):285-93. PubMed ID: 177968
    [No Abstract]   [Full Text] [Related]  

  • 39. Day treatment and psychotropic drugs in the aftercare of schizophrenic patients. A Veterans Administration cooperative study.
    Linn MW; Caffey EM; Klett CJ; Hogarty GE; Lamb HR
    Arch Gen Psychiatry; 1979 Sep; 36(10):1055-66. PubMed ID: 224831
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drug non-compliance in mania : the Indian experience.
    Khalkho IP; Khess CR
    Indian J Psychiatry; 1999 Apr; 41(2):108-10. PubMed ID: 21455372
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.